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For centuries human traits and diseases have been
associated with genetic markers. The association of specif-
ic hair color, nail contour and facial structure with certain
personality types has a long tradition in folklore and occult
sciences. The rate-limiting factor has been the availability
of measurable genetic markers. The first genetic marker was
reported in 19011 and it took a generation to identify the
second one.2 When the ABO blood groups were identified
as early biological markers under genetic control in the
early part of the twentieth century, they were promptly used
for association studies. The descriptions by Aird and his
colleagues of the associations of blood-group O with peptic
ulcer3,4 were reported in the 1950s and recently Davies et
al.5 confirmed the existence of a locus for type 1 diabetes
mellitus in the same region of chromosome 18 as the Kidd
blood group locus.6,7 There were 17 polymorphic blood
groups recognized in 1960s8 when isozymes took over. By
the mid-1970s there were 40-50 blood group antigens and
serum protein polymorphisms available as genetic markers.
Yet, these markers covered only 5-15% of the human
genome, and their genotyping was laborious, time-consum-
ing and technically demanding. 
About 150 protein polymorphisms were known in
1980s9, when they were superseded by nucleotide markers
identified as restriction fragment length polymorphisms
(RFLPs) by Botstein and colleagues.10 This discovery eased
the work of the geneticists greatly. RFLPs covered 85-90%
of the human genome and their genotyping was far more
simple and rapid than protein polymorphisms. These pow-
erful tools quickly led to major discoveries and the gene for
Huntington's disease was the first one successfully mapped
using RFLPs in 1983 by Gusella and colleagues.11 RFLP
analysis which required large amounts of DNA and 1-2
weeks of experimental work was soon overshadowed by
sequence polymorphisms revealed through the polymerase
chain reaction (PCR). 
There are several types of DNA sequence variations,
including insertions and deletions, differences in the copy
number of repeated sequences, and single base pair differ-
ences. They are widely distributed across the genome which
has brought mapping of disease genes within the realms of
practicality.
Genetic markers
The DNA sequence variations function as genetic
markers. A useful marker is polymorphic, i.e., exists in sev-
eral states. Genetic markers may not necessarily have func-
tional significance and therefore may not have any effect on
the phenotype. They can be derived from either coding or
noncoding regions of the genome. Most markers for genet-
ic studies have been derived from repetitive sequences in
the non-coding regions of the genome. Variable Number
Tandem Repeats (VNTRs) or minisatellites are 15 to 100
base pairs long sequences repeated several times at a partic-
ular locus in tandem. This variation at a locus is utilized in
DNA fingerprinting to identify individuals. In 1989, a novel
type of polymorphic marker called microsatellite was first
described.Error! Bookmark not defined. Microsatellites or
Short Tandem Repeats (STRs) are repetitive runs of DNA
similar to VNTRs but much shorter, usually di-, tri-, or
tetra- nucleotide repeats, flanked by unique sequences. The
human genome is estimated to have about 105 microsatel-
lite repeats distributed widely throughout the genome. The
repeat length of STRs is variable within populations and the
mutation rate is low, providing a rich source of multi-allelic
markers. These markers12,13, can produce genotyping data
within hours instead of weeks, using PCR technology.
Another class of polymorphisms involves the deletion or
insertion of DNA into an existing sequence. Deletions or
insertions may be as small as one base pair or may involve
the entire gene.
Single base pair differences are the most common of
DNA sequence variations.14 They are termed Single
Nucleotide Polymorphisms (SNPs) when the variant
sequence type has a frequency of at least 1% in the general
population. SNPs are generally biallelic genetic markers or
dimorphisms, such as a substitution C>T at position 825 in
exon 10 of GNB3 gene (GNB3 825 C>T), located on chro-
mosome 12p13.15 
Recently there has been considerable interest in the
use of SNPs for understanding the genetics of complex
human diseases.16 SNPs have many properties that make
them attractive for such investigations. Most importantly,
the genetic sequence variations that are responsible for
functional changes will often be SNPs, since they are the
most frequent and can occur in coding regions. SNPs with-
in protein-coding sequences are of particular interest
because they are more likely than a random SNP to have
functional significance. These may result in critical changes
in the gene-products resulting in pathogenic alterations.
SNPs in non-coding DNA also have functional conse-
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non-coding DNA also have functional conse-
quences, such as those in sequences that regulate gene
expression and intronic SNPs which create splice variants.
Discovery of SNPs that affect biological function will
become increasingly important over the next several years.
The GNB3 825 C>T dimorphism causes alternative splicing
in exon 9 resulting in deletion of 126 nucleotides and a sub-
sequent loss of 41 amino acids which constitutes one com-
plete domain of the Gi protein.15 This change leads to
enhanced signal transduction activity of the mutated Gi pro-
tein.17 Genotyping for possible functional polymorphisms is
of extreme significance and is known as 'direct' association
study strategy.16
Secondly, SNPs are far more abundant than
microsatellite polymorphisms (about once every 500-1000
base pairs) and hence are more powerful in fine mapping
chromosomal regions potentially harboring the disease
genes.18 In addition to their frequency of occurrence in the
genome, they are stable as they have much lower mutation
rates than do repeat sequences, such as STR. Thus, non-
functional SNPs lying in close physical proximity to dis-
ease-causing mutations can be effectively used to map chro-
mosomal regions of pathogenic significance. This is known
as the 'indirect' association study strategy.16
Thirdly, detection methods for SNPs are potentially
more amenable to being automated and used for large-scale
genetic analysis, due to the binary nature of SNPs. Thus,
high throughput genotyping of large number of markers is
feasible with the advent of microarray technologies.18
Therefore, SNPs will be particularly important for mapping
and discovering the genes associated with complex dis-
eases. 
Complex Disorders
Complex disorders refer to the characteristics or
traits of organisms that are determined by multiple genes,
usually with a significant environmental component as well.
They are thus polygenic and multifactorial. Examples of
complex disorders include cardiovascular diseases, dia-
betes, Alzheimer's, cancers and autoimmune disorders.
These traits do not follow a clear pattern of Mendelian
(monogenic) inheritance, where only single genes are
involved. 
In complex disorders, the interaction of multiple
genetic loci and their resulting effect on phenotypic expres-
sion and disease risk is far more complex than that of mono-
genic disorders. Genes for about 10,000 monogenic disor-
ders have been identified most of them resulting from sin-
gle, highly penetrant mutations. Complex disorders are not
the result of independent mutations in multiple genetic loci
rather it is their interaction, which in combination results in
the occurrence and variability of complex diseases. 
Complex disorders probably result from genetic
mutations that create only subtle changes in the function of
the gene-products. Due to this subtlety, gene hunters have
found it difficult to get a single "snapshot" of all the genes
that may be involved in these diseases.19 The genes
involved in complex disorders are often referred to as 'sus-
ceptibility genes,' since they increase the risk and predis-
pose individuals towards a particular disease. This distin-
guishes them from causative genes in which a mutation
directly leads to a particular phenotype, as in most
Mendelian disorders. 
The goal is to determine the genetic components of
complex disorders. To reach this goal several genetic map-
ping techniques have to be utilized to determine the location
of susceptibility genes. It is estimated that the human
genome has about 40,000 genes20 and trying to locate the
small number of susceptibility genes is like looking for the
proverbial needle in the haystack! This has led to the devel-
opment of several laboratory techniques coupled with elab-
orate theoretical and statistical armamentarium to help in
the search for disease-genes.
Linkage Analysis
Linkage analysis is just one of the several methods
that can be used to map genes, and is a part of a strategy
known as positional cloning. This term initially referred
only to the physical mapping and actual cloning of disease-
causing mutations. It originated from a general paradigm
that emerged from the study of single gene disorders, over
the past two decades. More recently positional cloning
refers to a complete process of identifying disease-genes,
from the initial study design to mutational analysis.21
Conventional methods of mapping genes such as fluores-
cent in situ hybridization, have been successfully used for
mapping genes that have already been identified. However,
the underlying biochemical defects for most diseases
remain unknown. Thus statistical linkage techniques which
do not require this information have become the key strate-
gy in positional cloning. 
Linkage is a method that allows the determination of
regions of chromosomes that are likely to contain a risk
gene, and rule out areas where there is a low chance of find-
ing a risk gene. Linkage works by using markers such as the
microsatellites, known to exist at specific chromosomal
locations. A family having members with the disease of
interest as well as healthy individuals, known as a pedigree,
is the first and foremost requirement for linkage analysis.
This method attempts to search for a marker that is consis-
tently present in those with the disease, and not present in
those without the condition. When a marker is found consis-
tently in the affected individuals of the family more com-
monly than in their healthy counterparts, the marker and the
marker and the disease-causing gene are said to be
linked, and are assumed to be very close together. Thus, this
approach identifies disease genes by their chromosomal
location, gradually zeroing in on them among their neigh-
bors in the genome.
The co-segregation of the marker with the disease-
causing mutation is essentially observed for its conformity
with Mendel's law of independent assortment. That is,
whether the alleles at the disease and marker loci segregate
independently according to Mendel's laws or tend to be
inherited together, violating Mendel's laws. While there
may be several possible explanations for this effect, the
most likely is that the two loci reside in close proximity to
each other. Alleles on the same chromosome should segre-
gate together at a rate that is proportional to the distance
between them. 
Linkage analysis has been used to find genes for
many disorders, including Huntington's disease Error!
Bookmark not defined. and Alzheimer's disease.22 There are
several downsides to using linkage. First, it requires the use
of DNA from both affected and unaffected individuals from
the same family. Second, linkage requires the use of DNA
from several pedigrees harboring the disease. Using mathe-
matical models Risch (1996) showed that linkage analysis
requires a huge sample size to derive the same volume of
information which can be obtained with a smaller sample
size, using association studies.Error! Bookmark not defined.
Lastly, linkage is a very time and labor intensive method.23
Association studies
Apart from linkage analysis the other major
approach to mapping disease susceptibility genes, is associ-
ation studies. Association is a statistical statement about the
co-occurrence of alleles and phenotypes. The simplest and
the most widely practiced model of association is a case-
control study. A large number of cases of a complex disor-
der, such as stroke, are compared with age and gender
matched controls from the same population for the frequen-
cy of the alleles of a specific marker in a candidate gene.
Allelic association is said to occur when there is a signifi-
cant change in the frequency of a marker allele for a disease
trait (phenotype) compared to the control population. This is
observed as deviations from the expected random occur-
rence of the alleles with respect to the disease phenotype.
Association can occur if the allele is itself directly responsi-
ble for a biological function, such as in the case of APOE-4
allele in Alzheimer's disease.24 This, as earlier mentioned, is
referred to as the direct-association study strategy. 
The indirect-association study strategy depends on
the concept of linkage disequilibrium (LD). LD occurs
when a marker allele lies in close proximity with the disease
susceptibility allele, such that these two alleles are inherited
together over several generations in the population studied.
Thus the same allele will be detected in affected individuals
from multiple unrelated families, but belonging to the same
population and thus to the same genetic pool. The concept
is similar to that which underlies linkage analysis, except
that linkage is studied within families and that, the chromo-
somal region mapped is much larger, owing to greater
genetic homogeneity of families compared to populations. 
The phenomenon which leads to linkage and linkage
disequilibrium is recombination, first postulated by the
American geneticist, Thomas Hunt Morgan. During meiosis
homologous chromosomes exchange genetic material. The
alleles at chromosomal loci undergoing crossing-over are
altered. Allelic recombination occurs at variable distances
along the chromosomes. Those alleles that lie in close phys-
ical proximity have a much lower chance of undergoing
recombination than those that lie further away from each
other. 
If a new mutation occurs in a gene leading to a dis-
ease phenotype and the mutation-harboring chromosome is
transmitted to several generations, the marker alleles at loci
further away from the mutation will undergo recombination
faster than those that are in close physical proximity with
the mutation. The closer the marker is to the disease gene,
the longer the allele-disease association will persist. Thus
the markers in close proximity with the mutation will appear
to cosegregate with the mutation. In such a case the marker
allele and the mutation are said to be linked and, there is
said to be an association between the marker allele and the
disease phenotype.
Thus, in 'direct' association studies a candidate gene
approach is used to test the hypothesis that an allele of a
given SNP increases disease susceptibility. This is achieved
by comparing the frequency of the candidate gene marker
(SNP) allele in affected versus unaffected individuals. If
reasonable candidate genes can be proposed for a disorder,
then association studies can be undertaken on these genes,
without the requirement of the presence of linkage disequi-
librium. The probability of observing an association for a
reasonable candidate gene is larger than for a randomly
selected marker allele. If an association is found, it could
still be due to linkage disequilibrium, and so determination
of the causative mutation may not be straightforward.
In 'indirect' association studies multiple SNPs are
used to search for evidence of an ancestral allele that is
enriched in affected individuals. Indeed, the chances of a
randomly selected marker to be of direct biological signifi-
cance and strongly associated with the complex phenotype
are low. Given the small distance over which LD extends
for biallelic SNPs25, the size of the human genome and the
low penetrance of the polymorphisms for complex traits. A
more reasonable role of indirect-association studies is in
extends for biallelic SNPs25, the size of the human
genome and the low penetrance of the polymorphisms for
complex traits. A more reasonable role of indirect-associa-
tion studies is in fine-mapping, once linkage studies have
indicated a region of interest for follow-up analysis.
Signals derived from genetic association studies tend
to be stronger than those produced by linkage analysis.
However, such investigations are experimental 'gambles',
since they are prone to a range of potential pitfalls (appro-
priate patients/controls and populations, fundamental genet-
ic complexity, technology limitations), many of which can-
not be controlled for. Large-scale association studies have
become feasible, because of the recent development of
genotyping strategies and a wide array of statistical tools. 
Example
The renin-angiotensin system (RAS) is one of the
most appealing candidate pathways for cardiovascular dis-
eases (CVD). Associations of various SNPs in the renin,
angiotensinogen, angiotensin-converting enzyme (ACE)
and angiotensin receptor genes could possibly be searched
for. There are several known polymorphisms in each of
these genes. The ACE insertion/deletion (I/D) polymor-
phism has attracted much attention of the scientific commu-
nity for its possible involvement in CVD. Since its discov-
ery in 199026, there has been an upsurge of association stud-
ies of the ACE I/D polymorphism and CVD. The D allele
was first shown to be associated with myocardial infarction
(MI).27 Studies in the rat showed increased rate of
angiotensin II production in the myocardium due to
increased ACE gene expression.28 If the relation between
the I/D polymorphism and serum ACE concentration was
extrapolated to the myocardium it would be logical to
expect higher angiotensin II generation in the heart and
coronaries of D/D individuals. Based on such possible
pathophysiological relations - the candidate gene approach
- a fascinating wave of studies was started in search of asso-
ciations between the D allele and CVD including stroke,
renovascular disease and MI.29 Even though after several
years of scientific endeavour and hundreds of association
studies of the I/D polymorphism and CVD resulted in con-
flicting results30,31, the ACE locus continued to remain of
much interest especially since linkage analysis reported two
QTL on long arm of chromosome 17.32 Recently a polymor-
phism in exon 17, ACE G2350A was reported to have the
most significant effect on plasma ACE concentration. After
adjustment for the effect of ACE G2350A polymorphism,
the I/D polymorphism was no longer associated with plas-
ma ACE concentration, indicating that it is in LD with ACE
G2350A and unlikely to be a functional mutation.33 We
recently reported an association of this dimorphism with
hypertension. Thus, the search for the functional mutation
continues and association studies are a major tool geneti-
cists have to undertake such an immense task.
Ethical Issues
The recent access to genome knowledge constitutes
a major scientific breakthrough, the implications of which
are still today difficult to grasp. This revolution has led to
legitimate worries. Genetic technology has great potential to
improve treatments and prevent human disease. On the
other hand, it also has the potential to cause great harm. 
The basic principles of ethics apply to all aspects of
medical practice, including medical genetics. They give a
guide as to what is ethically important and provide a con-
ceptual framework for discussing ethical issues. They do
not provide hard and fast rules. In genetics, as in other
aspects of medicine, ethical decision-making is complex
requiring sensitivity to context.
Thus, research programmes aimed at better defining
the ethical consequences of studies of the human genome
are greatly encouraged and supported. Moral questions, but
also those related to economy and public care are brought
about by the quick pace of genetic progress, and they lead
to very involved societal debates. Laws and regulations on
the applications of the new genetics are regularly adopted in
many countries.34,35
As we cross the threshold of the new millennium,
we simultaneously cross a threshold into an era where the
human genome sequence is largely known.  The genetic
markers thus discovered, may not only help in identifying
susceptibility genes for complex disorders but may also
have a huge impact on genetic diagnostic services, helping
to predict and prevent the occurrence of disease. We must
commit ourselves to exploring the application of these pow-
erful tools to the alleviation of human suffering, a mandate
that, undergrids all medicine.  At the same time, we must be
mindful of the great potential for misunderstanding of a
field that is developing very quickly, and make sure to
advance the ethical consideration of genetics with just as
much vigor as the medical research.
Glossary
Genetic Markers DNA sequence variations distributed
widely across the genome. 
Locus, a chromosomal region of DNA sequence variation 
Alleles are detectable variations occurring at a single genet-
ic locus
VNTR Variable Number Tandem Repeats (also called minisatel-
lites).
STR Short Tandem Repeats (also called microsatellite markers).
SNP Single Nucleotide Polymorphism. The alleles have a
SNP Single Nucleotide Polymorphism. The alleles have a
frequency of at least 1% in the general population.
Mutation The allele has a frequency less than 1% in the
general population and leads to a change in the protein pro-
duced (functional genetic alteration).
Dimorphism is a single base variation having two alleles at
corresponding chromosomal loci. 
Low Penetrance a few individuals in the population carry-
ing the allele causing the disease. 
Mendel's law of independent assortment states that genes
present on homologous chromosomes segregate from each
other and assort independently with other segregating chro-
mosomes during gamete formation.
'Direct' association study is carried out for diseases using
possible functional polymorphisms.
Complex disorders characteristics determined by multiple
genes, usually with a significant environmental component
as well.
Positional Cloning the complete process of identifying dis-
ease-genes, from the initial study design to mutational
analysis
Controls subjects enrolled in the study from the same pop-
ulation as the cases but free of disease. They constitute a
comparison, rather than a 'control' group, since it is not
known whether they will develop the disease in the future or
will continue to remain unaffected.
Candidate Gene A gene known to be involved in the patho-
physiology of the disease and thus hypothesized to be har-
boring the disease causing mutation.
Linkage Disequilibrium occurs when a marker allele lies
in close proximity with the disease susceptibility allele,
such that these two alleles are inherited together over sever-
al generations in the population.
'Indirect' association study multiple SNPs are used to
search for evidence of an ancestral allele (disease-causing)
that is enriched in affected individuals. They are based on
linkage disequilibrium mapping. 
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